What question did this study set out to answer?

This research aims to compare the effects of metabolic bariatric surgery and semaglutide on liver and extrahepatic health outcomes in patients with metabolic dysfunction-associated liver disease and type 2 diabetes.

April 15, 2026Open Access

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Key Points

This research aims to compare the effects of metabolic bariatric surgery and semaglutide on liver and extrahepatic health outcomes in patients with metabolic dysfunction-associated liver disease and type 2 diabetes.
Compared metabolic bariatric surgery with semaglutide in patients with metabolic dysfunction and type 2 diabetes
Evaluated hepatic and extrahepatic outcomes including cirrhosis and heart failure
Utilized liver assessment to inform treatment decisions
Increased risk of metabolic adverse liver outcomes was noted with metabolic bariatric surgery compared to semaglutide
Metabolic bariatric surgery showed protective effects against major adverse cardiovascular events
First diagnosis of cirrhosis and heart failure was more frequently observed with metabolic bariatric surgery

Abstract

In patients with MASLD and T2D, MBS, and specifically RYGB, as compared to semaglutide, may drive a relatively increased risk of MALO despite protection against MACE, the first diagnosis of cirrhosis, heart failure, and OAC. Liver evaluation in individuals with T2D referred for MBS may help optimize their treatment.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Stupalkowska et al. (Mon,) studied this question.

synapsesocial.com/papers/69df2b2ce4eeef8a2a6b01a7 https://doi.org/https://doi.org/10.1111/dom.70757

Bookmark

View Full Paper